# EDGAR Filing Document

**Accession Number:** 0001051514
**File Stem:** 0001140361-25-031629
**Filing Date:** 2025-8
**Character Count:** 31275
**Document Hash:** 353e58e00328e2251158ac00ed2cbda7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-031629.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001140361-25-031629

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 59

**CONFORMED PERIOD OF REPORT**: 20250818

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STRATA Skin Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001051514
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133986004
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51481
- **FILM NUMBER:** 251226311

**BUSINESS ADDRESS:**
- **STREET 1:** 5 WALNUT GROVE DRIVE
- **STREET 2:** SUITE 140
- **CITY:** HORSHAM
- **STATE:** PA
- **ZIP:** 19044
- **BUSINESS PHONE:** 215-619-3200

**MAIL ADDRESS:**
- **STREET 1:** 5 WALNUT GROVE DRIVE
- **STREET 2:** SUITE 140
- **CITY:** HORSHAM
- **STATE:** PA
- **ZIP:** 19044

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MELA SCIENCES, INC. /NY
- **DATE OF NAME CHANGE:** 20100504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ELECTRO OPTICAL SCIENCES INC /NY
- **DATE OF NAME CHANGE:** 19971216

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the

#### Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 18, 2025

![graphic](image0.jpg)

## STRATA SKIN SCIENCES, INC.
(Exact Name of Registrant Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br>| **000-51481**<br>| **13-3986004**<br>|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania** | &nbsp;&nbsp;&nbsp; **19044**<br>|
| (Address of Principal Executive Offices) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Zip Code) |

---

Registrant's telephone number, including area code: **215-619-3200**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br> Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share<br>| SSKN<br>| The NASDAQ Stock Market LLC<br>|

---

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure.** |

---

On August 18, 2025, STRATA Skin Sciences, Inc. (the "Company") posted an investor presentation to its website at <u>https://strataskinsciencesinc.gcs-web.com/</u>. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** Exhibits.

The following presentation is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be "filed":

<u>Exhibit No.</u> <u>Exhibit Description</u> <br> [99.1](ef20054078_ex99-1.htm) Investor Presentation dated August 2025, issued by Strata Skin Sciences, Inc. <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **STRATA SKIN SCIENCES, INC.** | **STRATA SKIN SCIENCES, INC.** |
| Date: August 18, 2025 | By: | /s/ John Gillings |
|  |  | John Gillings |
|  |  | Chief Accounting Officer |

---

------

## Exhibit 99.1

------

**Exhibit 99.1**<br>

![](ef20054078_ex99-1slide1.jpg)

Investor Presentation August 2025 Driving Value in Therapeutic and Aesthetic Dermatology NASDAQ: SSKN

------

![](ef20054078_ex99-1slide2.jpg)

Safe Harbor Statement 2 This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements regarding product development, product extensions, product integration or product marketing; any statements regarding continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, there are risks and uncertainties related to successfully integrating the products and employees of the Company, as well as the ability to ensure continued regulatory compliance, performance and/or market growth. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described in the reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to, implied or expressed in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments will cause its views to change. The information contained in this presentation speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

------

![](ef20054078_ex99-1slide3.jpg)

Investment Highlights 3 Global leader in advanced laser and light-based devices delivering unmatched efficacy and safety for serious skin disorders Existing Business is Operationally Cashflow Positive Cash from operations in 2024 was $0.2M Adjusting for 1x other income from the CARES Act of $0.9M and interest payments of $2.0M, the underlying cash from operations was $1.3M in 2024 TAM Increase of Greater than 3x on the Horizon; Potentially as Soon as January 2026 Historic CPT code expansion to unlock >30 million in covered potential patients Indications for use include ~30 new indications for inflammatory and autoimmune skin disorders 2026 Revenue opportunities with Temporary G-codes, if provisioned Increased Reimbursement per Patient Could Significantly Enhance TAM Expansion The Company has submitted economic data to support an increase in reimbursement per treatment LaserOptek Lawsuit Reduces Competition; Potential Multimillion $$ Damages Could Significantly Bolster Cash Position Strata sued LaserOptek for false advertising and unfair competition under the Lanham Act.

------

![](ef20054078_ex99-1slide4.jpg)

What We Do 4 The XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat multiple autoimmune disease conditions (e.g. Psoriasis, Vitiligo).1-3\* Quick and virtually painless without the troublesome side effects of other treatment options, it's simply a better way to long-lasting results.4-8\* TheraClear®X is a non-invasive, in-office acne treatment system specifically designed for the treatment of mild-to-moderate acne. TheraClearX's photopneumatic technology combines vacuum with broadband light delivered through a liquid cooled hand-held delivery system. The VTRAC Excimer Lamp System is a state-of-the art device with a water-cooled handpiece for maximum irradiance at 308nm. A light source, as opposed to a laser, VTRAC offers the targeted, therapeutic efficacy demonstrated by Excimer lasers, with the simplicity of design and reliability of a lamp system. \*1-8 see references section

------

![](ef20054078_ex99-1slide5.jpg)

Key Metrics 3 Stock Symbol NASDAQ: SSKN Stock Price (as of 8/1/25) $1.95 Shares Outstanding (as of 5/12/25) 4.2M Market Cap $8.2M Cash & Equivalents\* $7.8M Debt\* $15.2 Enterprise Value $15.6M Options\* Warrants\* 501,726 @ $8.36 WAEP 80,000 @ $8.80 WAEP Inside Ownership (%): ~39% \* As of 3/31/25

------

![](ef20054078_ex99-1slide6.jpg)

Business Model Recurring Revenue Business Model Revenue achieved through fee-per-use-based recurring procedures Reimbursed per procedure by Medicare and private payers Partnership - Recurring revenue driven by services that include turnkey practice solutions: No upfront capital expense DTC marketing patient sourcing and education Co-pay and reimbursement support Field service technical support Clinical training Proprietary Elevate 360 practice development consulting Goals for 2025 and Beyond Expand reimbursed indications for use Improve operational efficiencies Higher gross margins Expand revenue per device = higher recurring revenues Achieve positive EBITDA Grow positive cash flow from operations Establish strong foundation for potential M&A transaction 6

------

![](ef20054078_ex99-1slide7.jpg)

~1,000 Membership Agreements with Dermatology Providers Across the U.S. 7 Overview 844 Partner XTRAC® clinics + >150 sold XTRAC® devices 161 TheraClear®X clinics 5 Regions / 25 Sales Territories / 1 National Accounts Manager / National Capital Manager 14 Field Service Techs In-house call center and insurance benefits team 6 Clinical Specialists

------

![](ef20054078_ex99-1slide8.jpg)

XTRAC® Adds (Delegated)\* Reimbursed Recurring Revenue for Dermatology Partners 8 1 Specific Medicare payment rates vary depending on geographic indices assigned by Medicare. 2 At 20 (or 30) treatments per week, this represents 10 (or 15) patients in treatment (two treatments per week) at any one time. 3 Patient mix assumption: % of Patients with CPT Code 96920 (<250cm2): 33.33%; % of Patients with CPT Code 96921 (250-500cm2): 33.33%; % of Patients with CPT Code 96922 (>500cm2): 33.33% Cpt Code Description 2025 National Average Medicare Payment Rate1 96920 Excimer laser treatment for psoriasis; total area less than 250 sq. cm $136.83 96921 Excimer laser treatment for psoriasis; total area 250 sq. cm to 500 sq. cm $146.21 96922 Excimer laser treatment for psoriasis; total area over 250 sq. cm $182.76 MEDICARE REGION: NATIONAL AVERAGE # of Patients on XTRAC Treatments/ Year (Psoriasis/ Vitiligo/ Atopic Dermatitis) 25 50 100 Average # of Treatments / Patient / Year2 16 Total # of Treatments / Year 400 800 1600 Average Revenue Per Treatment3 $155.273 Physician Gross Revenue (Annual) $62,107 $124,213 $248,427 XTRAC LASER PHYSICIAN PARTNER UTILIZATION RATES: PARTNER VALUE OF AN XTRAC PATIENT Number of Treatments per patient Average Revenue Per Treatment3 16 $155.27 $2,492 x = 0800-8619

------

![](ef20054078_ex99-1slide9.jpg)

TheraClear®X Adds (Delegated)\* Reimbursed Recurring Revenue for Dermatology Partners 9 1 Specific Medicare payment rates vary depending on geographic indices assigned by Medicare. Cpt Code Description 2025 National Average Medicare Payment Rate1 10040 Acne Surgery, which Involves the opening or removal of multiple milia, comedones, cysts and pustules. $112.57 MEDICARE REGION: NATIONAL AVERAGE # of Acne Patients on THERACLEARX Treatments/ Year 100 200 300 Average # of Treatments / Patient 6 Total # of Treatments / Year 600 1200 1800 Average Revenue Per Treatment $112.57 Physician Gross Revenue (Annual) $67,542 $135,084 $202,626 THERACLEARX PHYSICIAN PARTNER UTILIZATION RATES: PARTNER VALUE OF A THERACLEARX PATIENT Number of Treatments per patient Average Revenue Per Treatment3 6 $112.57 $675.42 x = 0800-8619

------

![](ef20054078_ex99-1slide10.jpg)

Financial Metrics 10 (All numbers below in $'000s except for U.S. Installed Base) \*G&A reduced by ~$1.8M for 1x accrual of state sales tax

------

![](ef20054078_ex99-1slide11.jpg)

Diverse Dermatology Market OpportunitiesPsoriasis - $20.1B1, Vitiligo - $1.2B2, Eczema - $11.8B3, Acne - $5.5B4 11 30M Patients in the U.S. Psoriasis – 8M / Vitiligo - 5M / Eczema - 18M Fortune Business Insights Market Report 2019; 2016-2018 historical, 2019 base year, 2020-2027 projected Fortune Business Insights Market Report 2018; 2015-2017 historical, 2018 base year, 2019-2026 projected Market Data Forecast Analysis Report 2020; 2020 base year, 2021-2026 projected Strata Skin Sciences 50M+ Acne Patients in the U.S.

------

![](ef20054078_ex99-1slide12.jpg)

STRATA – Expansion and Growth Leverage Strata's Unique and Proven Business Model Best-in-class devices Recurring revenue driven by DTC and internally-driven, growing installed base Turn-key services suite for practices without an upfront capital spend Elevate 360 Consulting - Optimizing growth through Recurring Revenue per Device DTC marketing in U.S. with potential 40% revenue increase /device More rigorous sales and marketing strategy Focused growth initiatives targeting double digit revenue growth and positive cash flow 12

------

![](ef20054078_ex99-1slide13.jpg)

Newly Expanded Indications & Enhanced Reimbursement Unlocking Growth 13 May 2025: CPT® Editorial Summary of Panel Actions \| AMA AMA accepted CPT code revision is effective from 1/1/202 Triples Strata's XTRAC Addressable Patient Population From ~10M (psoriasis only) to 30M+ patients covering all Inflammatory Skin Diseases, including vitiligo, atopic dermatitis, alopecia areata, and more, effective 1/1/27 Increases Economic Value for both Providers & Strata Accelerating access through Temporary G-codes to potentially commence new treatment revenue in 2026 Clear Path to Value: Bigger patient pool & improved economics for providers and Strata Higher per-procedure revenue potential from proposed increases for device-related practice expense values In May 2025, the AMA CPT Editorial Panel revised CPT codes, enabling reimbursement for 30 new indications with its the XTRAC excimer laser

------

![](ef20054078_ex99-1slide14.jpg)

Value Drivers 2025 Initiatives To Increase Growth In Recurring Revenue Per Device In The U.S. Market 14 Emphasis on higher per practice performance through improved patient lead-to-procedure conversion and high touch, value-add support services i.e., reimbursement administration, scheduling, and enhanced process efficiencies Strategic Placements - Reduce lower performing practices, redistributing devices among growing Greater Efficiency and Treatment Capacity - Enhanced turn-key marketing, administration and reimbursement More rigorous sales and marketing strategies and processes Increased revenue/device - Emphasis on DTC marketing (social media advertising) in U.S. Initiatives could collectively grow revenue by double digit percent

------

![](ef20054078_ex99-1slide15.jpg)

Turn-Key Solutions to Ensure Practice Success 15 No upfront capital expense; fee-per-use business model Complete business solution includes a suite of value-added support services to maximize practice's success Clinical Support Reimbursement Support Call Center Support Field Service Support Consumables and Parts Device Upgrades Co-pay Support DTC Marketing PartnershipProgram

------

![](ef20054078_ex99-1slide16.jpg)

Unique Go-to-Market Strategy 16 Partners supported through a complete business solution model PE-backed Group Partnership accounts represent 37% of XTRAC domestic recurring accounts

------

![](ef20054078_ex99-1slide17.jpg)

Co-op Marketing And Practice-generated Content Creates Additional Awareness 17 Branded promotional materials for in-office use & patient awareness Patient Brochures Counter Cards Waiting Room Videos Digital branded assets for practice web page & social media platforms Email Blasts Social Media Posts Program Awareness Co-Op Advertising Mailers/Postcards

------

![](ef20054078_ex99-1slide18.jpg)

DTC Advertising Generates Direct and Indirect Appointments in Partner Clinics 18 PATIENT JOURNEY Patients see XTRAC ad on Facebook, Google and Instagram Click on the ad to go to an XTRAC page and leave their contact information In-house call center team confirms appointment and insurance benefits Patients show in the office Prescribed XTRAC Start XTRAC 1 2 3 4 5 6 50,000+ patients see an XTRAC everyday.

------

![](ef20054078_ex99-1slide19.jpg)

DTC Core Driver for Recurring Revenue 19 DTC drives patient population in the clinic at a 2:1 ratio, increasing organic prescribed patients (Halo Effect).

------

![](ef20054078_ex99-1slide20.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Domestic XTRAC® Installed Base Growth Drivers 844 2,361 358 As of 6/30/2025 Signed strategic expansion into group clinic rollups Within the 43 groups: 78 TheraClear®X devices Penetration grew from 86 in 2018 to 358 in 2024 Group partnership accounts represent 37% of XTRAC® domestic recurring revenue XTRAC®Partners GroupClinics 20 Representative PE Backed Groups: Over 250 comeback opportunities of existing excimer laser owners Increased penetration into facility locations (e.g. Kaiser, VA, and Mt. Sinai)

------

![](ef20054078_ex99-1slide21.jpg)

Reducing Number of Underperforming Centers Drives Increasing Revenues per Device/Reduces CapEx Needs 21 Average Recurring Revenue/Device US Installed Base

------

![](ef20054078_ex99-1slide22.jpg)

2Q25 Financial Highlights 22 Revenue Total revenue $7.7M (-9% YOY) vs. $8.4M 2Q24, primarily due to challenging international markets; underlying demand remains strong across regions and growth expectations remain Global net recurring revenue $5.1M (-4% YOY) US gross recurring billings per device of $5,512 (+3% YOY) XTRAC gross US recurrent billings $4.6M (-2% YOY) vs. $4.7M 2Q24 Equipment revenue of $2.5M (-18% YOY) Gross Profit Gross profit $4.2M (58% of revenue) vs. $4.9M 2Q24, primarily due to lower volumes Operating Expenses Operating expenses $6.1M (+6% YOY) from 2Q24 Cash Flow $6M cash as of June 30, 2025

------

![](ef20054078_ex99-1slide23.jpg)

International Sales Operations India Israel S. Korea Japan China Bahrain, Iraq, Jordan, Kuwait, Qatar, Oman, Saudi Arabia, UAE Mexico In-house Head of International Sales 48 international partner XTRAC® clinics (S. Korea, Japan) as of June 2025 Capital equipment sales preferred model rather than U.S. turn-key Usage per device higher than in U.S. market TheraClear®X equipment sales opportunity Latin America & European markets untapped Total International Install Base >1,700 devices Markets added in 2023 STRATA's international markets 23 ($000s) International Sales

------

![](ef20054078_ex99-1slide24.jpg)

Affiliated Academic Institutions STRATA has placed over 50 XTRAC® machines in residency programs across academic institutions 24 Affiliated Academic Institutions STRATA devices are available at over 50 academic institutes that offer dermatology residency programs 24

------

![](ef20054078_ex99-1slide25.jpg)

XTRAC for Psoriasis, Vilitigo, and Eczema

------

![](ef20054078_ex99-1slide26.jpg)

XTRAC®: Overview Safe, effective treatment 350+ peer-reviewed clinical studies Psoriasis treatment is the number 1 domestic use for XTRAC® lasers – 80% of treatments Opportunities exist for expanding use for other approved indications like vitiligo and eczema Clinical support team focused on: In-office training Best practices 26

------

![](ef20054078_ex99-1slide27.jpg)

Indicated for Chronic Dermatological Diseases Visible skin disorders can limit healthy psychosocial development and have profoundly negative consequences on quality of life3-5 VITILIGO ~7.5 million adults in the US1,a PSORIASIS ATOPIC DERMATITIS ~2–3 million adults in the US2 ~16.5 million adults in the US3 1. Armstrong AW et al. JAMA Dermatol. 2021;157(8):940-946.aIncludes people 20 years of age and older. 2. Gandhi K et al. JAMA Dermatol. 2022;158(1):43-50. 3. Fuxench ZCC et al. J Invest Dermatol. 2019;139(3):583-590.4. Elbuluk N, Ezzedine K. Dermatol Clin. 2017;35:117-128. 5. Armstrong AW, Read C. JAMA. 2020;323(19):1945-1960. 27

------

![](ef20054078_ex99-1slide28.jpg)

Induces Apoptosis of T cells and Keratinocytes in Psoriatic Plaques 28 Baseline After 2 tx After 4 tx XTRAC® Psoriasis Clinical Protocol - 6.2 treatments to PASI\* 75 Induces apoptosis in T cells and keratinocytes1 T cell Keratinocytes Psoriasis: Autoimmune disease that causes the skin to regenerate faster than normal; characterized by red, itchy scaly patches \*PASI – A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis Tx- treatments 1. Abrouk M et al. Psoriasis Targets Ther. 2016;6:165-173. 2. Esmat S et al. Dermatol Clin. 2017;35:171-192. 3. Oh CT et al. Lasers Surg Med. 2016;48(6):629-637, XTRAC® Targeted 308nm UVB

------

![](ef20054078_ex99-1slide29.jpg)

Induces Melanocyte Proliferation and T cell Apoptosis in Vitiligo Patches 29 Baseline After 18 tx After 21 tx XTRAC® Vitiligo Clinical Protocol - >75% repigmentation in less than 20 treatments1 Vitiligo: An autoimmune condition due to a loss of melanocytes, characterized by white patches of skin losing its pigment Long lasting results No pigment loss during 2-year follow-up2 80% facial repigmentation retention at 3-year follow-up3 XTRAC® Targeted 308nm UVB Stimulates melanocyte proliferation and induces T cell apoptosis2 Melanocyte T cell Shi Q et al. Photodermatol Photoimmunol Photomed. 2013;29(1):27-33. 2. Esposito M et al. Clin Exp Dermatol. 2004;29:133-137. 3. Hong SB et al. J Korean Med Sci. 2005;20:273-278 Hadi S et al. Photomed Laser Surg. 2006; 24(3):354-357 Sethi S, Silverberg NB. J Drugs Dermatol.2022;21(7):773-775.

------

![](ef20054078_ex99-1slide30.jpg)

Source: National Psoriasis Foundation XTRAC® is a Preferred Treatment for 90% of Psoriasis Patients (<10% BSA) 30

------

![](ef20054078_ex99-1slide31.jpg)

Has Clinical and Economic Competitive Advantage 31 XTRAC® NB-UVB Topical Steroids Non-Biologic Systemics Biologics Approximate Costs ($) 1K-3K 3K-9K 1K-7K 1K 32K-68K Clinical Outcomes 92% 71% 75% 48% 50-70% Speed of Onset 5 10 3 14 12 Days of Actual Care 18 80 294 52 12-65 Remission 2.5 Months Continued with maintenance Continued with maintenance Continued with maintenance Continued with maintenance Adverse Events Mild Temp Mild Temp Mild-Mod Temp –Lasting Mild-Severe Temp – Lasting Mild-Severe Temp – Lasting Marchetti A, Bhutani T, Lockshin B, Siegel DM, Behringer F. Therapies for Psoriasis: Clinical and Economic Comparisons. J Drugs Dermatol. 2020 Nov 1;19(11):1101-1108. doi: 10.36849/JDD.2020.5510. PMID: 33196750

------

![](ef20054078_ex99-1slide32.jpg)

TheraClearXfor Acne

------

![](ef20054078_ex99-1slide33.jpg)

TheraClear®X: Overview Safe, effective treatment Peer-reviewed clinical studies Opportunities exist for expanding use for expanding the installed base to clinics using reimbursed acne surgery procedures Clinical support team focused on: In-office training Best practices 33

------

![](ef20054078_ex99-1slide34.jpg)

Acne is the Most Common Skin Condition in Dermatology Up to 50 Million Americans affected annually2 ~85% of all adolescents experience some degree of acne from the ages of 12 to 24 years3 >50% of US women experience acne in their 20s4 Acne occurring in adults is increasing5 #1 skin disease in the US1 Bickers DR et al. J Am Acad Dermatol. 2006;55:490-500. Tan JKL, Bhate K. Br J Dermatol. 2015;172 (Suppl 10:3-12. White GM. J Am Acad Dermatol. 1998;39:S34-S37. Collier CN et al. J Am Acad Dermatol. 2008;58:56-59. Holzmann R, Shakery K. Skin Pharmacol Physiol. 2014;27 (Suppl 1):3-8. 34

------

![](ef20054078_ex99-1slide35.jpg)

Photopneumatic Technology Combines VACUUM with PULSED BROADBAND LIGHT 35 Clears bacteria and follicular contents from pilosebaceous unit, C acnes are removed both mechanically and thermally from the active acne lesion. Reduces sebum production cleans pores by extracting sebaceous and follicular material light activates porphyrins to directly reduce C acnes and sebum production skin normalizes upon completion Place Extract Treat Complete contact with treatment area Baseline After 4 treatments Photos courtesy of Suneel Chilukuri, MD.

------

![](ef20054078_ex99-1slide36.jpg)

Addresses Limitations of Existing Acne Therapies 36 Visible improvement of acne lesions as early as after second treatment Visible improvement of skin texture, pore size, and perilesional erythema after the first few treatments Time to improvement Initiation 4 to 6 treatments, scheduled 1-2 weeks apart Maintenance1 to 2 months apart as needed Treatment regimen Procedure ~15 minutes per treatment No pre-treatment with topical analgesics Comfortable with no down time Can be delegated (depending on state laws) Systemic and topical acne treatments Are often associated with poor adherence due to forgetfulness, inconvenience, and adverse effects1,2 Typically require 3 to 6 weeks to achieve visible improvement3 Can be associated with skin dryness, irritation, burning, and bleaching effects2 TheraClear®X Comfortable in-office treatment with no down-time Visible improvement of acne lesions as early as after second treatment Visible improvement of skin texture, pore size, and perilesional erythema after the first few treatments Snyder S et al. Am J Clin Dermatol. 2014;15(2):87-94. 2. Tuchayi SM et al. Patient Pref Adherence. 2016;10:2091-2096 3. Fox L et al. Molecules. 2016;21:1063. doi:10.3390/molecules21081063. 4. Data on file. STRATA Skin Sciences.

------

![](ef20054078_ex99-1slide37.jpg)

Seasoned Management Team Sales and Operational Dermatology Experience Chief Executive Officer Dr. Dolev Rafaeli V.P. Finance John Gillings Chief Operating Officer Shmuel Gov 37

------

![](ef20054078_ex99-1slide38.jpg)

Investment Highlights 38 Leading, global, commercial-stage medical device company marketing laser, photopneumatic and advanced light-sourced device technology that treats serious skin disorders with unmatched efficacy and safety Multi-billion $ market opportunity across Psoriasis, Vitiligo, Eczema, and Acne markets Validated with over 350 peer-reviewed, published studies Multi-faceted Recurring Revenue Growth Model Revenue driven by both recurring patient procedures (US) and device sales and service (Int'l) Partnership Model - comprehensive, turnkey services suite for derm practices with no upfront costs Elevate 360 Consulting model facilitating higher patient conversion and increased device utilization in underperforming dermatology partner clinics Expanding recurring revenue placements in international markets Strategic initiatives drive growth in the business Threefold TAM expansion as CPT code changes unlock 30 million patient market; following expanded reimbursement coverage for XTRACT 308nm excimer laser by the American Medical Association CPT editorial panel Indications for use to include multiple inflammatory and autoimmune skin disorders; adds vitiligo, atopic dermatitis, etc., among ~30 new indications Temporary G-codes potentially pull forward reimbursement in 2026 from 1/1/2027 effective date

------

![](ef20054078_ex99-1slide39.jpg)

References 39 XTRAC 510K Summary. Published January 14, 2020. Niwa Y, Hasegawa T, Ko S, et al. Efficacy of 308-nm excimer light for Japanese patients with psoriasis. J Dermatol. 2009;36(11):579-582. Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study. J Am Acad of Dermatol. 2002;46(6):900-906. Taneja A, Trehan M, Taylor C. 308-nm Excimer Laser for the Treatment of Psoriasis –Induration-Based Dosimetry. Arch Dermatol. 2003;139(6):759-764. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad of Dermatol. 2008;58:826-50. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad of Dermatol. 2009;61:451-85 Menter A, Korman NJ, Elmets CA. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad of Dermatol. 2009;60:643-59. Fikrle T and Pizinger K. The use of the 308 nm excimer laser for the treatment of psoriasis.

------

![](ef20054078_ex99-1slide40.jpg)

For More Information Investor Contact: CORE IR 516-222-2560 IR@strataskin.com www.strataskinsciences.com Thank You.

------

![](ef20054078_ex99-1slide41.jpg)

APPENDIX

------

![](ef20054078_ex99-1slide42.jpg)

Provider engagement and education and through conferences/ webinars 42 AAD Global Vitiligo Foundation CalDerm Fall Clinical

------

![](ef20054078_ex99-1slide43.jpg)

Acquisitions to Drive Top-line Growth January 2022 August 2021 $3.7M Acquisition Minimal acquisition cost compared to exclusivity in external laser market $1M Acquisition Adds attractive business segment to address $5.5B acne market 43

------

![](ef20054078_ex99-1slide44.jpg)

Example – NYC Metro Area XTRAC® Placements and DTC Leads (2H24) 44 Metro NYC XTRAC® installed base Metro NYC 2H24 DTC Patient Leads

------

![](ef20054078_ex99-1slide45.jpg)

Psoriasis Case Study: Patient I.B., Lewisburg, PA 45 Treatment Room After Before

------